Reza Sari Motlagh1,2, Keiichiro Mori1,3, Ekaterina Laukhtina1,4, Abdulmajeed Aydh1,5, Satoshi Katayama1,6, Nico C Grossmann1,7, Hadi Mostafai1,8, Benjamin Pradere1,9, Fahad Quhal1,10, Victor M Schuettfort1,11, Mohammad Reza Roshandel12, Pierre I Karakiewicz13, Jeremy Teoh14, Shahrokh F Shariat1,4,15,16,17,18,19,20, Harun Fajkovic1. 1. Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria. 2. Men's Health and Reproductive Health Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3. Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. 4. Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. 5. Department of Urology, King Faisal Medical City, Abha, Saudi Arabia. 6. Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. 7. Department of Urology, University Hospital Zurich, Zurich, Switzerland. 8. Research Centre for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. 9. Department of Urology, University Hospital of Tours, Tours, France. 10. Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. 11. Department of Urology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. 12. Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 13. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada. 14. S.H.Ho Urology, Department of Surgery, Chinese University of Hong Kong, Hong Kong, China. 15. Department of Urology, Weill Cornell Medical College, New York, NY, USA. 16. Department of Urology, University of Texas Southwestern, Dallas, TX, USA. 17. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. 18. Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. 19. Division of Urology, Department of Special Surgery, Jordan University Hospital, University of Jordan, Amman, Jordan. 20. European Association of Urology Research Foundation, Arnhem, the Netherlands.
Abstract
OBJECTIVE: To assess whether single immediate intravesical chemotherapy (SIIC) adds value to bladder tumour management in combination with novel optical techniques: enhanced transurethral resection of bladder tumour (TURBT). METHODS: A systematic search was performed using the PubMed and Web of Science databases in September 2020 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) extension statement for network meta-analyses. Studies that compared recurrence rates among intervention groups (TURBT with photodynamic diagnosis [PDD] ± SIIC, narrow-band imaging [NBI] ± SIIC, or white-light cystoscopy [WLC] + SIIC) and a control group (TURBT with WLC alone) were included. We used the Bayesian approach in the network meta-analysis. RESULTS: Twenty-two studies (n = 4519) met our eligibility criteria. Out of six different interventions including three different optical techniques, compared to WLC alone, blue-light cystoscopy (BLC) plus SIIC (odds ratio [OR] 0.349, 95% credible interval [CrI] 0.196-0.601) and BLC alone (OR 0.668, 95% CrI 0.459-0.931) were associated with a significantly lower likelihood of 12-month recurrence rate. In the sensitivity analysis, out of eight different interventions compared to WLC alone, PDD by 5-aminolevulinic acid plus SIIC (OR 0.327, 95% CrI 0.159-0.646) and by hexaminolevulinic acid plus SIIC (OR 0.376, 95% CrI 0.172-0.783) were both associated with a significantly lower likelihood of 12-month recurrence rate. NBI with and without SIIC was not associated with a significantly lower likelihood of 12-month recurrence rate (OR 0.385, 95% CrI 0.105-1.29 and OR 0.653, 95% CrI 0.343-1.15). CONCLUSION: Blue-light cystoscopy during TURBT with concomitant SIIC seems to yield superior recurrence outcomes in patients with non-muscle-invasive bladder cancer. The use of PDD was able to reduce the 12-month recurrence rate; moreover, concomitant SIIC increased this risk benefit by a 32% additional reduction in odds ratio. Although using PDD could reduce the recurrence rate, SIIC remains necessary. Moreover, ranking analysis showed that both PDD and NBI, plus SIIC, were better than these techniques alone.
OBJECTIVE: To assess whether single immediate intravesical chemotherapy (SIIC) adds value to bladder tumour management in combination with novel optical techniques: enhanced transurethral resection of bladder tumour (TURBT). METHODS: A systematic search was performed using the PubMed and Web of Science databases in September 2020 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) extension statement for network meta-analyses. Studies that compared recurrence rates among intervention groups (TURBT with photodynamic diagnosis [PDD] ± SIIC, narrow-band imaging [NBI] ± SIIC, or white-light cystoscopy [WLC] + SIIC) and a control group (TURBT with WLC alone) were included. We used the Bayesian approach in the network meta-analysis. RESULTS: Twenty-two studies (n = 4519) met our eligibility criteria. Out of six different interventions including three different optical techniques, compared to WLC alone, blue-light cystoscopy (BLC) plus SIIC (odds ratio [OR] 0.349, 95% credible interval [CrI] 0.196-0.601) and BLC alone (OR 0.668, 95% CrI 0.459-0.931) were associated with a significantly lower likelihood of 12-month recurrence rate. In the sensitivity analysis, out of eight different interventions compared to WLC alone, PDD by 5-aminolevulinic acid plus SIIC (OR 0.327, 95% CrI 0.159-0.646) and by hexaminolevulinic acid plus SIIC (OR 0.376, 95% CrI 0.172-0.783) were both associated with a significantly lower likelihood of 12-month recurrence rate. NBI with and without SIIC was not associated with a significantly lower likelihood of 12-month recurrence rate (OR 0.385, 95% CrI 0.105-1.29 and OR 0.653, 95% CrI 0.343-1.15). CONCLUSION: Blue-light cystoscopy during TURBT with concomitant SIIC seems to yield superior recurrence outcomes in patients with non-muscle-invasive bladder cancer. The use of PDD was able to reduce the 12-month recurrence rate; moreover, concomitant SIIC increased this risk benefit by a 32% additional reduction in odds ratio. Although using PDD could reduce the recurrence rate, SIIC remains necessary. Moreover, ranking analysis showed that both PDD and NBI, plus SIIC, were better than these techniques alone.
Authors: Lillian Y Lai; Sean M Tafuri; Emily C Ginier; Lindsey A Herrel; Philipp Dahm; Philipp Maisch; Giulia Ippolito Lane Journal: Cochrane Database Syst Rev Date: 2022-04-08